Characteristics of CMV-seropositive patients undergoing CBT, stratified by CMV prevention strategy
| . | Letermovir (N = 21) . | High-dose valacyclovir (N = 40) . | P* . |
|---|---|---|---|
| Age, y, median (IQR) | 43.0 (39.2-55.5) | 25.8 (9.8-37.6) | <.001 |
| Sex | .19 | ||
| Female | 10 (48) | 26 (65) | |
| Male | 11 (52) | 14 (35) | |
| Transplantation year, range | 2018-2019 | 2014-2017 | |
| Number of donors | .21 | ||
| 1 | 5 (24) | 16 (40) | |
| 2 | 16 (76) | 24 (60) | |
| HLA disparity† | .875 | ||
| 4/6 | 16 (76) | 32 (80) | |
| 5/6 | 4 (19) | 6 (15) | |
| 6/6 | 1 (5) | 2 (5) | |
| Conditioning regimen | .27 | ||
| Myeloablative | 19 (90) | 39 (98) | |
| Nonmyeloablative | 2 (10) | 1 (3) | |
| Total nucleated cell dose (×107/kg), median (IQR) | 4.8 (4.0-5.4) | 7.2 (5.4-10.9) | .003 |
| Diagnosis | .005 | ||
| Acute lymphoblastic leukemia | 5 (24) | 21 (53) | |
| Acute myelogenous leukemia | 6 (29) | 13 (33) | |
| Myelodysplastic syndrome | 5 (24) | 0 (0) | |
| Other | 5 (24) | 6 (15) | |
| Acute graft-versus-host disease | .10 | ||
| Grades 0 to 1 | 9 (43) | 10 (25) | |
| Grades 2 to 4 | 11 (52) | 30 (75) | |
| Missing | 1 (5) | 0 (0) | |
| Absolute lymphocyte count (cells/mm3) at day +98, median (IQR)‡ | 650 (450-1008) | 645 (392-980) | .48 |
| Antiviral duration for CS-CMVi, d, median (IQR) | |||
| Day 0 to 98 period | 26 (21.5-33.5) | 52.5 (43-63.5) | .03 |
| Day 99 to 365 period | 28 (25-50) | 25.5 (20-40) | .2 |
| . | Letermovir (N = 21) . | High-dose valacyclovir (N = 40) . | P* . |
|---|---|---|---|
| Age, y, median (IQR) | 43.0 (39.2-55.5) | 25.8 (9.8-37.6) | <.001 |
| Sex | .19 | ||
| Female | 10 (48) | 26 (65) | |
| Male | 11 (52) | 14 (35) | |
| Transplantation year, range | 2018-2019 | 2014-2017 | |
| Number of donors | .21 | ||
| 1 | 5 (24) | 16 (40) | |
| 2 | 16 (76) | 24 (60) | |
| HLA disparity† | .875 | ||
| 4/6 | 16 (76) | 32 (80) | |
| 5/6 | 4 (19) | 6 (15) | |
| 6/6 | 1 (5) | 2 (5) | |
| Conditioning regimen | .27 | ||
| Myeloablative | 19 (90) | 39 (98) | |
| Nonmyeloablative | 2 (10) | 1 (3) | |
| Total nucleated cell dose (×107/kg), median (IQR) | 4.8 (4.0-5.4) | 7.2 (5.4-10.9) | .003 |
| Diagnosis | .005 | ||
| Acute lymphoblastic leukemia | 5 (24) | 21 (53) | |
| Acute myelogenous leukemia | 6 (29) | 13 (33) | |
| Myelodysplastic syndrome | 5 (24) | 0 (0) | |
| Other | 5 (24) | 6 (15) | |
| Acute graft-versus-host disease | .10 | ||
| Grades 0 to 1 | 9 (43) | 10 (25) | |
| Grades 2 to 4 | 11 (52) | 30 (75) | |
| Missing | 1 (5) | 0 (0) | |
| Absolute lymphocyte count (cells/mm3) at day +98, median (IQR)‡ | 650 (450-1008) | 645 (392-980) | .48 |
| Antiviral duration for CS-CMVi, d, median (IQR) | |||
| Day 0 to 98 period | 26 (21.5-33.5) | 52.5 (43-63.5) | .03 |
| Day 99 to 365 period | 28 (25-50) | 25.5 (20-40) | .2 |
Data are presented as no. (%) unless otherwise indicated.
χ2 test and Fisher's exact test were used for categorical variables, as appropriate; Wilcoxon rank-sum test was used to compare medians for continuous variables.
For recipients of 2 cord blood units, the HLA matching reflects the unit with the lowest match.
Data included for patients from each cohort with results within 7 d of day +98 (n = 19 and 38, respectively). Among the 18 individuals in the letermovir cohort with CMV monitoring data beyond day +98, absolute lymphocyte count values were similar among those who subsequently developed CS-CMVi (n = 9; 830 cells/mm3; IQR, 610-1230) compared with those who did not (n = 9; 500 cells/mm3; 325-895).